Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
- PMID: 17557954
- DOI: 10.1200/JCO.2006.09.7634
Phase II study of erlotinib in patients with malignant pleural mesothelioma: a Southwest Oncology Group Study
Abstract
Purpose: Malignant pleural mesothelioma (MPM) expresses high levels of epidermal growth factor receptor (EGFR), and preclinical studies have identified antitumor activity of EGFR tyrosine kinase inhibitors (TKIs) in MPM. We conducted a phase II trial of the EGFR TKI erlotinib in previously untreated patients with MPM.
Patients and methods: Patients with measurable and nonmeasurable disease were treated with erlotinib 150 mg/d on days 1 through 28 of each 28-day dosing cycle. Archived patient tumors were analyzed for immunohistochemical expression of EGFR, phospho-EGFR, human epidermal growth factor receptor 2 (HER2), phospho-extracellular signal-regulated kinase (ERK), and phosphatase and tensin homolog (PTEN) and phosphorylation of members of the phosphatidylinositol 3-kinase/Akt signaling pathway.
Results: Sixty-three patients were treated on the study. EGFR was highly expressed in 75% of patient tumors, as was phospho-ERK (82%), phospho-Akt (84%), phospho-mammalian target of rapamycin (74%), and phospho-forkhead (74%). HER2 was rarely expressed, and loss of PTEN was rare. For 33 patients with measurable disease, there were no objective responses; 14 patients (42%) had stable disease, 15 patients (45%) had disease progression, and four patients had inadequate assessments to determine response. Toxicities were mainly constitutional (51%), dermatologic (82%), and GI (52%); there was one death on trial, which was related to dyspnea. Median overall survival time was 10 months; 1-year survival rate was 43%; and median progression-free survival time was 2 months.
Conclusion: Single-agent erlotinib was not effective in MPM, despite high expression of EGFR. Activation of the ERK and phosphatidylinositol 3-kinase/Akt downstream pathways are possible resistance mechanisms to EGFR TKI. The activated phosphatidylinositol 3-kinase/Akt pathway is a potential therapeutic target for MPM.
Similar articles
-
Gefitinib in patients with malignant mesothelioma: a phase II study by the Cancer and Leukemia Group B.Clin Cancer Res. 2005 Mar 15;11(6):2300-4. doi: 10.1158/1078-0432.CCR-04-1940. Clin Cancer Res. 2005. PMID: 15788680 Clinical Trial.
-
Inhibition of epidermal growth factor receptor signaling in malignant pleural mesothelioma.Cancer Res. 2002 Sep 15;62(18):5242-7. Cancer Res. 2002. PMID: 12234991
-
Preclinical investigation of folate receptor-targeted nanoparticles for photodynamic therapy of malignant pleural mesothelioma.Int J Oncol. 2018 Nov;53(5):2034-2046. doi: 10.3892/ijo.2018.4555. Epub 2018 Sep 7. Int J Oncol. 2018. PMID: 30226590 Free PMC article.
-
Targeted epidermal growth factor receptor therapy in malignant pleural mesothelioma: where do we stand?Cancer Treat Rev. 2011 Nov;37(7):533-42. doi: 10.1016/j.ctrv.2010.11.004. Epub 2010 Dec 22. Cancer Treat Rev. 2011. PMID: 21183281 Review.
-
Molecular targets in malignant pleural mesothelioma treatment.Curr Drug Targets. 2009 Dec;10(12):1235-44. doi: 10.2174/138945009789753200. Curr Drug Targets. 2009. PMID: 19909234 Review.
Cited by
-
Emerging New Targets in Systemic Therapy for Malignant Pleural Mesothelioma.Cancers (Basel). 2024 Mar 22;16(7):1252. doi: 10.3390/cancers16071252. Cancers (Basel). 2024. PMID: 38610930 Free PMC article. Review.
-
Reflecting real-world patients with mesothelioma in research: an interim report of baseline characteristics from the ASSESS-meso cohort.ERJ Open Res. 2023 Dec 27;9(6):00467-2023. doi: 10.1183/23120541.00467-2023. eCollection 2023 Nov. ERJ Open Res. 2023. PMID: 38174143 Free PMC article.
-
Targeted Approaches to Treatment of Pleural Mesothelioma: A Review.JCO Precis Oncol. 2023 Sep;7:e2300344. doi: 10.1200/PO.23.00344. JCO Precis Oncol. 2023. PMID: 37992257 Review.
-
Improvements in Systemic Therapies for Advanced Malignant Mesothelioma.Int J Mol Sci. 2023 Jun 21;24(13):10415. doi: 10.3390/ijms241310415. Int J Mol Sci. 2023. PMID: 37445594 Free PMC article. Review.
-
Indolyl-chalcone derivatives trigger apoptosis in cisplatin-resistant mesothelioma cells through aberrant tubulin polymerization and deregulation of microtubule-associated proteins.Front Oncol. 2023 May 25;13:1190988. doi: 10.3389/fonc.2023.1190988. eCollection 2023. Front Oncol. 2023. PMID: 37305581 Free PMC article.
Publication types
MeSH terms
Substances
Grants and funding
- CA37981/CA/NCI NIH HHS/United States
- CA58416/CA/NCI NIH HHS/United States
- CA45560/CA/NCI NIH HHS/United States
- CA76462/CA/NCI NIH HHS/United States
- CA35178/CA/NCI NIH HHS/United States
- CA13612/CA/NCI NIH HHS/United States
- CA45807/CA/NCI NIH HHS/United States
- CA22433/CA/NCI NIH HHS/United States
- CA35431/CA/NCI NIH HHS/United States
- CA12644/CA/NCI NIH HHS/United States
- CA20319/CA/NCI NIH HHS/United States
- CA45808/CA/NCI NIH HHS/United States
- CA58882/CA/NCI NIH HHS/United States
- CA45377/CA/NCI NIH HHS/United States
- CA11083/CA/NCI NIH HHS/United States
- CA58861/CA/NCI NIH HHS/United States
- CA35090/CA/NCI NIH HHS/United States
- CA16385/CA/NCI NIH HHS/United States
- CA46441/CA/NCI NIH HHS/United States
- CA46368/CA/NCI NIH HHS/United States
- CA32102/CA/NCI NIH HHS/United States
- CA38926/CA/NCI NIH HHS/United States
- CA46113/CA/NCI NIH HHS/United States
- CA27057/CA/NCI NIH HHS/United States
- CA42777/CA/NCI NIH HHS/United States
- P30 CA006927/CA/NCI NIH HHS/United States
- CA67575/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Research Materials
Miscellaneous